TY - JOUR
T1 - Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment
T2 - The NOSANO-study
AU - Hermus, Merel
AU - van der Wilk, Berend J.
AU - Chang, Rebecca T.H.
AU - Collee, Gerlise
AU - Noordman, Bo J.
AU - Coene, Peter Paul L.O.
AU - Dekker, Jan Willem T.
AU - Hartgrink, Henk H.
AU - Heisterkamp, Joos
AU - Nieuwenhuijzen, Grard A.P.
AU - Rosman, Camiel
AU - Timmermans, Liesbeth
AU - Wijnhoven, Bas P.L.
AU - van der Zijden, Charlène J.
AU - Busschbach, Jan J.
AU - van Lanschot, J. Jan B.
AU - Lagarde, Sjoerd M.
AU - Kranenburg, Leonieke W.
N1 - Funding information:
Maag Lever Darm Stichting, Grant/Award
Number: ZP-18-13
Publisher Copyright:
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
PY - 2022/10/27
Y1 - 2022/10/27
N2 - Active surveillance may be a safe and effective treatment in oesophageal cancer patients with a clinically complete response after neoadjuvant chemoradiotherapy (nCRT). In the NOSANO-study we gained insight in patients' motive to opt for either an experimental treatment called active surveillance or for standard immediate surgery. Both qualitative and quantitative analyses methods were used. Forty patients were interviewed about their treatment preference, 3 months after completion of nCRT (T1). Data were recorded, transcribed verbatim and analysed according to the principles of grounded theory. In addition, at T1 and T2 (12 months after completion of nCRT) questionnaires on health-related quality of life, coping, anxiety and decisional regret (only T2) were administered. Interview data analyses resulted in a conceptual model with ‘dealing with threat of cancer’ as the central theme. Patients preferring active surveillance tend to cope with this threat by confiding in their bodies and good outcomes. Their mind-set is one of ‘enjoy life now’. Patients preferring surgery tend to cope by minimizing uncertainty and eliminating the source of cancer. Their mind-set is one of ‘don't give up, act now’. Furthermore, questionnaire results showed that patients with a preference for standard surgery had a lower quality of life. Patient preferences are individualized and thus difficult to predict. Our model can help healthcare professionals to determine patient preferences for treatment. Coping style and mind-set seem to be determining factors here.
AB - Active surveillance may be a safe and effective treatment in oesophageal cancer patients with a clinically complete response after neoadjuvant chemoradiotherapy (nCRT). In the NOSANO-study we gained insight in patients' motive to opt for either an experimental treatment called active surveillance or for standard immediate surgery. Both qualitative and quantitative analyses methods were used. Forty patients were interviewed about their treatment preference, 3 months after completion of nCRT (T1). Data were recorded, transcribed verbatim and analysed according to the principles of grounded theory. In addition, at T1 and T2 (12 months after completion of nCRT) questionnaires on health-related quality of life, coping, anxiety and decisional regret (only T2) were administered. Interview data analyses resulted in a conceptual model with ‘dealing with threat of cancer’ as the central theme. Patients preferring active surveillance tend to cope with this threat by confiding in their bodies and good outcomes. Their mind-set is one of ‘enjoy life now’. Patients preferring surgery tend to cope by minimizing uncertainty and eliminating the source of cancer. Their mind-set is one of ‘don't give up, act now’. Furthermore, questionnaire results showed that patients with a preference for standard surgery had a lower quality of life. Patient preferences are individualized and thus difficult to predict. Our model can help healthcare professionals to determine patient preferences for treatment. Coping style and mind-set seem to be determining factors here.
UR - http://www.scopus.com/inward/record.url?scp=85141345407&partnerID=8YFLogxK
U2 - 10.1002/ijc.34327
DO - 10.1002/ijc.34327
M3 - Article
C2 - 36250325
AN - SCOPUS:85141345407
VL - 152
SP - 1183
EP - 1190
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 6
ER -